18[F]F AraG - CellSight Technologies

Drug Profile

18[F]F AraG - CellSight Technologies

Alternative Names: 18[F]F-AraG; 18F-AraG; AraG-18[F]F; F18F-AraG; VisAcT

Latest Information Update: 14 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stanford University
  • Developer CellSight Technologies
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Bladder cancer; Cancer; Head and neck cancer

Most Recent Events

  • 08 Nov 2017 CellSight Technologies signs a collaboration agreement with Boehringer Ingelheim to evaluate 18[F]F AraG in immuno-oncological therapies
  • 17 Oct 2017 University of California, San Francisco and CellSight Technologies plan a phase II trial for Non-small cell lung cancer (Diagnosis) in USA (IV) (NCT03311672)
  • 08 May 2017 CellSight Technologies initiates a phase I trial in Cancer (Diagnosis) in USA (NCT03142204)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top